MAAT Stock Overview
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
MaaT Pharma SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €9.32 |
52 Week High | €10.60 |
52 Week Low | €4.50 |
Beta | 0.21 |
1 Month Change | 6.88% |
3 Month Change | 30.17% |
1 Year Change | -9.51% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -33.19% |
Recent News & Updates
Recent updates
Shareholder Returns
MAAT | FR Biotechs | FR Market | |
---|---|---|---|
7D | 0.6% | -0.2% | -0.4% |
1Y | -9.5% | -1.8% | 10.6% |
Return vs Industry: MAAT underperformed the French Biotechs industry which returned -2.2% over the past year.
Return vs Market: MAAT underperformed the French Market which returned 10.1% over the past year.
Price Volatility
MAAT volatility | |
---|---|
MAAT Average Weekly Movement | 8.9% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.3% |
10% most volatile stocks in FR Market | 10.0% |
10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: MAAT's share price has been volatile over the past 3 months.
Volatility Over Time: MAAT's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 51 | Herve Affagard | https://www.maatpharma.com |
MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.
MaaT Pharma SA Fundamentals Summary
MAAT fundamental statistics | |
---|---|
Market cap | €108.27m |
Earnings (TTM) | -€14.73m |
Revenue (TTM) | €2.31m |
46.8x
P/S Ratio-7.3x
P/E RatioIs MAAT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MAAT income statement (TTM) | |
---|---|
Revenue | €2.31m |
Cost of Revenue | €854.00k |
Gross Profit | €1.46m |
Other Expenses | €16.19m |
Earnings | -€14.73m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Mar 28, 2024
Earnings per share (EPS) | -1.27 |
Gross Margin | 63.09% |
Net Profit Margin | -636.60% |
Debt/Equity Ratio | 39.7% |
How did MAAT perform over the long term?
See historical performance and comparison